These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25566405)

  • 1. Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital.
    Maraki S; Samonis G; Dimopoulou D; Mantadakis E
    Infect Chemother; 2014 Dec; 46(4):253-6. PubMed ID: 25566405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant
    Dadashi M; Sharifian P; Bostanshirin N; Hajikhani B; Bostanghadiri N; Khosravi-Dehaghi N; van Belkum A; Darban-Sarokhalil D
    Front Med (Lausanne); 2021; 8():720647. PubMed ID: 34568377
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimicrobial susceptibility of enterococci recovered from healthy cattle, pigs and chickens in nine EU countries (EASSA Study) to critically important antibiotics.
    de Jong A; Simjee S; Garch FE; Moyaert H; Rose M; Youala M; Dry M;
    Vet Microbiol; 2018 Mar; 216():168-175. PubMed ID: 29519512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
    Williams JD; Maskell JP; Whiley AC; Sefton AM
    J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
    Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Typing of Enterococcus spp. strains in 4 hospitals in the Małopolska region in Poland.
    Talaga K; Odrowąż-Konduracka D; Paradowska B; Jagiencarz-Starzec B; Wolak Z; Bulanda M; Szczypta A
    Adv Clin Exp Med; 2018 Jan; 27(1):111-117. PubMed ID: 29521051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Epidemiology of Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Clinical Specimens in the Northwest of Iran.
    Jahansepas A; Ahangarzadeh Rezaee M; Hasani A; Sharifi Y; Rahnamaye Farzami M; Dolatyar A; Aghazadeh M
    Microb Drug Resist; 2018 Oct; 24(8):1165-1173. PubMed ID: 29708837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
    Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
    Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibilities of clinical isolates of vancomycin-resistant enterococci in Taiwan.
    Hsueh PR; Wu JJ; Lu JJ; Teng LJ; Luh KT
    J Formos Med Assoc; 1999 Jan; 98(1):45-8. PubMed ID: 10063273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
    Reis AO; Cordeiro JC; Machado AM; Sader HS
    Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance mechanisms and clinical characteristics of linezolid-resistant Enterococcus faecium isolates: A single-centre study in South Korea.
    Cho SY; Kim HM; Chung DR; Kim SH; Huh HJ; Kang CI; Peck KR; Lee NY; Song JH
    J Glob Antimicrob Resist; 2018 Mar; 12():44-47. PubMed ID: 28941790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian Group on Antimicrobial Resistance Enterococcus Surveillance Programme annual report, 2010.
    Coombs GW; Pearson JC; Christiansen K; Gottlieb T; Bell JM; George N; Turnidge JD;
    Commun Dis Intell Q Rep; 2013 Sep; 37(3):E199-209. PubMed ID: 24890955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008.
    Bérenger R; Bourdon N; Auzou M; Leclercq R; Cattoir V
    Med Mal Infect; 2011 Aug; 41(8):405-9. PubMed ID: 21550192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.